Comparison between positron emission tomography and computed tomography in the use of the assessment of esophageal carcinoma

Kato, Hiroyuki; Kuwano, Hiroyuki; Nakajima, Masahiro; Miyazaki, Tatsuya; Yoshikawa, Minako; Ojima, Hitoshi; Tsukada, Katsuhiko; Oriuchi, Noboru; Inoue, Tomio; Endo, Keigo

doi:10.1002/cncr.10330

Cited by 275 publications

(110 citation statements)

References 25 publications

(38 reference statements)

Supporting

Mentioning

100

Contrasting

Unclassified

Order By: Relevance

“…18 F-FDG PET/CT is a metabolic imaging method and its usefulness in esophageal cancer patients has been reported in several studies (9,10,11,12). SUV has been widely used parameter for evaluation of FDG uptake degree of several tumor types.…”

Section: Discussionmentioning

confidence: 99%

Prognostic Value of Metabolic Tumor Volume Measured by 18F-FDG PET/CT in Esophageal Cancer Patients

Soydal¹,

Yüksel²,

No³

et al. 2014

Mirt

View full text Add to dashboard Cite

Objective: In this study, we aimed to explore prognostic importance of definition of preoperative metabolic tumor volume in esophageal cancer patients.Methods: 22 patients who have histologically proven stage IIA-III esophageal cancer and underwent 18F-FDG PET/CT for preoperative staging of disease were included to the study. After 18F-FDG PET/CT, all the patients underwent surgery within 4 weeks period. Patients have been followed up until death or Sept 15th, 2012. Dates of death were recorded for survival analysis. During evaluation of 18F-FDG PET/CT images, metabolic tumor volumes were calculated by drawing the isocontour region of interests from all visually positive FGD uptake lesions.Results: 22 patients (15M, 7F; mean age: 65.1±8.4, min-max:48-80) underwent 18F-FDG PET/CT for preoperative staging of esophageal cancer. Preoperative diagnosis was squamous cell and adeno cancer in 17 (%77) and 5 (%23) patients, respectively. Location of primary tumor is distal, proximal and mid-esophagus in 13 (%59), 6 (%27) and 3 (%13) patients, respectively. Primary tumor of all the patients were FDG avid (mean SUVmax: 18.85±7.0; range: 5.5-35.1). Additionally, 18F-FDG uptake was seen in mediastinal lymph nodes in 13 patients (5.45±8.15; range: 2.6-29.9). Mean metabolic tumor volumes of primary esophageal lesions were calculated as 8.77±8.46cm3 (range: 2.3-34.2). Mean MTV of lymph nodes was 2.44±1.01cm3 (range: 0.4-3.6). Mean total metabolic tumor volume was calculated as 9.99±8.58cm3 (range: 2.3-27.3). 10 patients died during 447±121 days follow-up period. Mean survival time was 11.9±1.5 months (95%CI: 8.99-14.74) for entire patient group. Total metabolic tumor volume had a significant effect on survival (p=0.045) according to Cox proportional hazards regression analysis. One unit increase in MTV caused 1.1 (95%CI:1.003-1.196) fold increase in hazard, at any time.Conclusion: Definition of preoperative metabolic tumor volume has a prognostic value in the prediction of postoperative survival times. Patients who have higher preoperative metabolic tumor volumes could be good candidates for more aggressive chemo-radiation therapy regiments.Conflict of interest:None declared.

show abstract

Section: Discussionmentioning

confidence: 99%

Prognostic Value of Metabolic Tumor Volume Measured by 18F-FDG PET/CT in Esophageal Cancer Patients

Soydal¹,

Yüksel²,

No³

et al. 2014

Mirt

View full text Add to dashboard Cite

show abstract

“…As for ESCC, a markedly increased FDG uptake has been documented previously [22,23,24,25,26], and PET is rapidly developing into a noninvasive method for preoperative staging. However, the impact of PET on the detection of locoregional lymph node (LN) metastasis is still unsatisfactory.…”

Section: Introductionmentioning

confidence: 99%

The Relationship between the Glucose Transporter Type 1 Expression and <sup>18</sup>F-Fluorodeoxyglucose Uptake in Esophageal Squamous Cell Carcinoma

Hiyoshi

Watanabe²,

Imamura³

et al. 2009

Oncology

View full text Add to dashboard Cite

Objective: Glucose transporter type 1 (Glut1) has been reported to be present in several types of carcinomas. The aims of this study are to evaluate Glut1 expression in both primary tumors and metastatic lymph nodes (LNs) of esophageal squamous cell carcinoma (ESCC) and to assess the relationship between Glut1 expression and ¹⁸F-fluorodeoxyglucose (FDG) accumulation. Methods: We immunohistochemically examined the expression of Glut1 in 60 surgically resected primary lesions and 95 metastatic LNs of ESCC and classified them into 3 groups. The FDG accumulation was assessed with a positron emission tomography (PET). Results: In the primary tumors, a high Glut1 expression was found to be significantly associated with advanced lesions: depth of tumor (p < 0.01), LN metastasis (p < 0.05) and advanced pathological stage (p < 0.01). The Glut1 expression of the metastatic LNs significantly correlated with that of each primary tumor (p < 0.001). The PET-positive lesions had a larger size and higher Glut1 expression than the PET-negative lesions in both the primary tumors and metastatic LNs. Conclusions: In both the primary tumors and metastatic LNs of ESCC, the Glut1 expression and tumor size correlated with the FDG accumulation and influence the sensitivity of the PET scan.

show abstract

“…In summary, most studies (12 of 15) showed that pretreatment FDG uptake is a predictor for survival in univariate analysis, whereas only 2 studies showed FDG uptake to be a predictor of survival in multivariate analysis 30–33,35,36,39,43,44,53,55,56. More importantly, neither of the 2 largest prospective trials could prove the prognostic significance of FDG-PET 52,56…”

Section: Resultsmentioning

confidence: 99%

“…30–44,52–56 In the second group, 6 studies described decrease in FDG uptake measured early during neoadjuvant therapy (group 2A: Table 3), and also 10 studies described decrease in FDG uptake measured after completion of neoadjuvant therapy (group 2B: Table 3). 14,16,38,41,42,45–51,55,57–59 Also, 9 studies described the same cohorts of patients; however these were not excluded 31,32,35,36,41,42,47,49,51. Methodological aspects of included studies are described in Tables 4, 5, and 6.…”

Section: Resultsmentioning

confidence: 99%

“…This study is limited by the lack of multivariate analysis. In 2002 Kato et al showed that FDG uptake was associated with depth of tumor invasion, presence of lymph node metastases, and lymphatic vessel invasion in 32 patients 35. The 2-year survival rate in patients with high FDG uptake (48%) was lower than in patients with low FDG uptake (91%).…”

Section: Resultsmentioning

confidence: 99%

See 1 more Smart Citation

FDG-PET Parameters as Prognostic Factor in Esophageal Cancer Patients: A Review

et al. 2011

View full text Add to dashboard Cite

Background18F-fluorodeoxyglucose positron emission tomography (FDG-PET) has been used extensively to explore whether FDG Uptake can be used to provide prognostic information for esophageal cancer patients. The aim of the present review is to evaluate the literature available to date concerning the potential prognostic value of FDG uptake in esophageal cancer patients, in terms of absolute pretreatment values and of decrease in FDG uptake during or after neoadjuvant therapy.MethodsA computer-aided search of the English language literature concerning esophageal cancer and standardized uptake values was performed. This search focused on clinical studies evaluating the prognostic value of FDG uptake as an absolute value or the decrease in FDG uptake and using overall mortality and/or disease-related mortality as an end point.ResultsIn total, 31 studies met the predefined criteria. Two main groups were identified based on the tested prognostic parameter: (1) FDG uptake and (2) decrease in FDG uptake. Most studies showed that pretreatment FDG uptake and postneoadjuvant treatment FDG uptake, as absolute values, are predictors for survival in univariate analysis. Moreover, early decrease in FDG uptake during neoadjuvant therapy is predictive for response and survival in most studies described. However, late decrease in FDG uptake after completion of neoadjuvant therapy was predictive for pathological response and survival in only 2 of 6 studies.ConclusionsMeasuring decrease in FDG uptake early during neoadjuvant therapy is most appealing, moreover because the observed range of values expressed as relative decrease to discriminate responding from nonresponding patients is very small. At present inter-institutional comparison of results is difficult because several different normalization factors for FDG uptake are in use. Therefore, more research focusing on standardization of protocols and inter-institutional differences should be performed, before a PET-guided algorithm can be universally advocated.

show abstract

Comparison between positron emission tomography and computed tomography in the use of the assessment of esophageal carcinoma

Cited by 275 publications

References 25 publications

Prognostic Value of Metabolic Tumor Volume Measured by 18F-FDG PET/CT in Esophageal Cancer Patients

Prognostic Value of Metabolic Tumor Volume Measured by 18F-FDG PET/CT in Esophageal Cancer Patients

The Relationship between the Glucose Transporter Type 1 Expression and <sup>18</sup>F-Fluorodeoxyglucose Uptake in Esophageal Squamous Cell Carcinoma

FDG-PET Parameters as Prognostic Factor in Esophageal Cancer Patients: A Review

Contact Info

Product

Resources

About